Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK- positive non-small cell lung cancer (NSCLC).
Camidge D, Bang Y, Kwak E, Shaw A, Iafrate A, Maki R, Solomon B, Ou S, Salgia R, Wilner K, Costa D, Shapiro G, LoRusso P, Stephenson P, Tang Y, Ruffner K, Clark J. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK- positive non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2011, 29: 2501-2501. DOI: 10.1200/jco.2011.29.15_suppl.2501.Peer-Reviewed Original Research